Literature DB >> 28187514

AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.

Michael N Dworzak1, Barbara Buldini2, Giuseppe Gaipa3, Richard Ratei4, Ondrej Hrusak5, Drorit Luria6, Eti Rosenthal7, Jean-Pierre Bourquin8, Mary Sartor9, Angela Schumich1, Leonid Karawajew10, Ester Mejstrikova5, Oscar Maglia3, Georg Mann1, Wolf-Dieter Ludwig4, Andrea Biondi3, Martin Schrappe11, Giuseppe Basso2.   

Abstract

Immunophenotyping by flow cytometry (FCM) is a worldwide mainstay in leukemia diagnostics. For concordant multicentric application, however, a gap exists between available classification systems, technologic standardization, and clinical needs. The AIEOP-BFM consortium induced an extensive standardization and validation effort between its nine national reference laboratories collaborating in immunophenotyping of pediatric acute lymphoblastic leukemia (ALL). We elaborated common guidelines which take advantage of the possibilities of multi-color FCM: marker panel requirements, immunological blast gating, in-sample controls, tri-partite antigen expression rating (negative vs. weak or strong positive) with capturing of blast cell heterogeneities and subclone formation, refined ALL subclassification, and a dominant lineage assignment algorithm able to distinguish "simple" from bilineal/"complex" mixed phenotype acute leukemia (MPAL) cases, which is essential for choice of treatment. These guidelines are a first step toward necessary inter-laboratory standardization of pediatric leukemia immunophenotyping for a concordant multicentric application.
© 2017 International Clinical Cytometry Society. © 2017 International Clinical Cytometry Society.

Entities:  

Keywords:  flow cytometry; immunophenotyping:; leukemia; pediatric; standardization

Mesh:

Year:  2017        PMID: 28187514     DOI: 10.1002/cyto.b.21518

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  24 in total

1.  CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia.

Authors:  Dagmar Schinnerl; Ester Mejstrikova; Angela Schumich; Marketa Zaliova; Klaus Fortschegger; Karin Nebral; Andishe Attarbaschi; Karel Fiser; Maximilian O Kauer; Niko Popitsch; Sabrina Haslinger; Andrea Inthal; Barbara Buldini; Giuseppe Basso; Jean-Pierre Bourquin; Giuseppe Gaipa; Monika Brüggemann; Tamar Feuerstein; Margarita Maurer-Granofszky; Renate Panzer-Grümayer; Jan Trka; Georg Mann; Oskar A Haas; Ondrej Hrusak; Michael N Dworzak; Sabine Strehl
Journal:  Haematologica       Date:  2019-01-31       Impact factor: 9.941

2.  Heterogeneity of childhood acute leukemia with mature B-cell immunophenotype.

Authors:  Irina Demina; Elena Zerkalenkova; Olga Illarionova; Yulia Olshanskaya; Tatiana Verzhbitskaya; Alexandra Semchenkova; Grigory Tsaur; Ekaterina Rusanova; Margarita Belogurova; Ludmila Baidun; Svetlana Plyasunova; Tatiana Konyuhova; Anna Kazakova; Larisa Fechina; Galina Novichkova; Elena Samochatova; Natalia Myakova; Alexey Maschan; Alexander M Popov
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-28       Impact factor: 4.553

Review 3.  Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy.

Authors:  Alejandro Gutierrez; Alex Kentsis
Journal:  Br J Haematol       Date:  2018-02-14       Impact factor: 6.998

4.  Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force.

Authors:  Etan Orgel; Thomas B Alexander; Brent L Wood; Samir B Kahwash; Meenakshi Devidas; Yunfeng Dai; Todd A Alonzo; Charles G Mullighan; Hiroto Inaba; Stephen P Hunger; Elizabeth A Raetz; Alan S Gamis; Karen R Rabin; Andrew J Carroll; Nyla A Heerema; Jason N Berman; William G Woods; Mignon L Loh; Patrick A Zweidler-McKay; John T Horan
Journal:  Cancer       Date:  2019-10-29       Impact factor: 6.860

5.  Distribution of subtypes and immunophenotypic characterization of 1379 cases of paediatric acute leukaemia.

Authors:  Saba Jamal; Fatima Meraj; Neelum Mansoor; Sadia Parveen; Ameerah Shaikh; Naeem Jabbar
Journal:  Pak J Med Sci       Date:  2021 May-Jun       Impact factor: 1.088

6.  Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of ex vivo treated pediatric T-cell acute lymphoblastic leukemia cells.

Authors:  Daniela Kuzilková; Cristina Bugarin; Katerina Rejlova; Axel R Schulz; Henrik E Mei; Maddalena Paganin; Alessandra Biffi; Andrea Biondi; Tomas Kalina; Giuseppe Gaipa
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

7.  Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols.

Authors:  Gunnar Cario; Veronica Leoni; Valentino Conter; Andishe Attarbaschi; Marketa Zaliova; Lucie Sramkova; Gianni Cazzaniga; Grazia Fazio; Rosemary Sutton; Sarah Elitzur; Shai Izraeli; Melchior Lauten; Franco Locatelli; Giuseppe Basso; Barbara Buldini; Anke K Bergmann; Jana Lentes; Doris Steinemann; Gudrun Göhring; Brigitte Schlegelberger; Oskar A Haas; Denis Schewe; Swantje Buchmann; Anja Moericke; Deborah White; Tamas Revesz; Martin Stanulla; Georg Mann; Nicole Bodmer; Nira Arad-Cohen; Jan Zuna; Maria Grazia Valsecchi; Martin Zimmermann; Martin Schrappe; Andrea Biondi
Journal:  Haematologica       Date:  2019-10-10       Impact factor: 9.941

8.  The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.

Authors:  Beat Bornhauser; Gunnar Cario; Anna Rinaldi; Thomas Risch; Virginia Rodriguez Martinez; Moritz Schütte; Hans-Jörg Warnatz; Nastassja Scheidegger; Paulina Mirkowska; Martina Temperli; Claudia Möller; Angela Schumich; Michael Dworzak; Andishe Attarbaschi; Monika Brüggemann; Mathias Ritgen; Ester Mejstrikova; Andreas Hofmann; Barbara Buldini; Pamela Scarparo; Giuseppe Basso; Oscar Maglia; Giuseppe Gaipa; Tessa-Lara Skoblyn; Geertruij Te Kronnie; Elena Vendramini; Renate Panzer-Grümayer; Malwine Jeanette Barz; Blerim Marovca; Mathias Hauri-Hohl; Felix Niggli; Cornelia Eckert; Martin Schrappe; Martin Stanulla; Martin Zimmermann; Bernd Wollscheid; Marie-Laure Yaspo; Jean-Pierre Bourquin
Journal:  Blood Adv       Date:  2020-09-08

9.  A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia.

Authors:  Yi Li; Xiwen Tong; Lifang Huang; Li Li; Chunyan Wang; Cheng He; Songya Liu; Zhiqiong Wang; Min Xiao; Xia Mao; Donghua Zhang
Journal:  Cancer Med       Date:  2021-06-01       Impact factor: 4.452

10.  Copy Number Alteration Profile Provides Additional Prognostic Value for Acute Lymphoblastic Leukemia Patients Treated on BFM Protocols.

Authors:  Mirella Ampatzidou; Lina Florentin; Vassilios Papadakis; Georgios Paterakis; Marianna Tzanoudaki; Dimitra Bouzarelou; Stefanos I Papadhimitriou; Sophia Polychronopoulou
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.